Table 1.
Demographic and baseline characteristics.
| General population (n=201) | AAE group (n=75) | non-AAE group (n=126) | P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age | 59.11 ± 12.46 | 63.11 ± 11.13 | 57.59 ± 11.47 | 0.001 † |
| Gender | 0.625 ‡ | |||
| Male | 162 | 60 (80.0) | 102 (81.0) | |
| Female | 39 | 16 (21.3) | 23 (18.3) | |
| Risk factors and comorbidities | ||||
| Hypertension | 151 (75.1) | 61 (81.3) | 90(71.4) | 0.067 ‡ |
| Smoking | 54 (26.9) | 21 (28.0) | 33 (26.2) | 0.780 ‡ |
| Alcohol | 23 (11.4) | 5 (6.7) | 18 (14.3) | 0.101 ‡ |
| Diabetes | 18 (89.6) | 5 (6.7) | 13 (10.3) | 0.381 ‡ |
| History of CAD | 10 (49.8) | 2 (2.7) | 8 (6.4) | 0.246 ‡ |
| History of AMI | 1 (0.5) | 0 | 1 (0.8) | 0.194 ‡ |
| History of CVD | 6 (29.9) | 1 (1.3) | 5 (4.0) | 0.288 ‡ |
| History of CKD | 6 (29.9) | 2 (2.7) | 4 (3.2) | 0.838 ‡ |
| Medication on admission | ||||
| Antiplatelet | 9 (4.5) | 3 (4.0) | 6 (4.8) | 0.801 ‡ |
| Anticoagulant | 1 (0.5) | 0 | 1 (0.8) | 0.194 ‡ |
| Statin | 6 (2.9) | 2 (2.7) | 4 (3.2) | 0.838 ‡ |
| Phase | 175 (80.6) | 0.221 ‡ | ||
| Acute | 131 (65.2) | 47 (62.7) | 84 (66.7) | |
| Subacute | 30 (14.9) | 12 (16.0) | 18 (14.3) | |
| chronic | 14 (7.0) | 2 (2.7) | 12 (9.5) | |
| Location of primary intimal tear | 0.592 ‡ | |||
| Z3 | 127 (63.2) | 39 (52.0) | 88 (69.8) | |
| Z4 | 9 (4.5) | 2 (2.7) | 7 (5.6) | |
| The length of proximal landing zone (mm) | 1.72 | 1.67 | 1.74 | 0.400 † |
| Length of stent-graft (mm) | 184.3 | 186 | 183.5 | 0.605 † |
| Adjunctive procedures | 13 (6.5) | 3 (4.0) | 10 (7.9) | 0.272 ‡ |
| Preoperative hematological parameters | ||||
| Serum creatinine (>115μmol/L) | 43 (21.4) | 16 (21.3) | 27 (21.4) | 0.987 ‡ |
| eGFR (<100 ml/min/1.73m2) | 149 (74.1) | 57 (76.0) | 92 (73.0) | 0.640 ‡ |
| Cholesterol (mmol/L) | 17 (8.5) | 7 (9.3) | 10 (7.9) | 0.537 ‡ |
| Triglycerides (mmol/L) | 33 (16.4) | 7 (9.3) | 26 (20.6) | 0.068 ‡ |
| LDL (mmol/L) | 50 (24.9) | 20 (26.7) | 30 (23.8) | 0.714 ‡ |
| HDL (mmol/L) | 42 (20.9) | 10 (13.3) | 32 (25.4) | 0.084 ‡ |
| Albumin (<35g/L) | 75 (37.3) | 30 (40.0) | 45 (35.7) | 0.055 ‡ |
| WBC (×109/L) | 75 (37.3) | 26 (34.7) | 49 (38.9) | 0.549 † |
| Neutrophil (×109/L) | 74 (36.8) | 32 (42.7) | 42 (33.3) | 0.001 † |
| Monocyte (×109/L) | 75 (37.3) | 19 (25.3) | 56 (44.4) | 0.002 † |
| Lymphocyte (×109/L) | 69 (34.3) | 32 (42.7) | 37 (29.4) | 0.001 † |
| Platelet (×109/L) | 40 (19.9) | 11 (14.7) | 29 (23.0) | 0.004 † |
| NLR (>5.105) | 55 (27.4) | 25 (33.3) | 30 (23.8) | < 0.001 ‡ |
| MLR (>0.675) | 74 (36.8) | 23 (30.7) | 51 (40.5) | 0.163 ‡ |
| PLR (>127.985) | 61 (30.3) | 44 (58.7) | 17 (13.5) | < 0.001 ‡ |
| SII (>596.910) | 152 (75.6) | 67 (89.3) | 85 (67.5) | < 0.001 ‡ |
| SIRI (>3.990) | 76 (37.8) | 53 (70.7) | 23 (18.3) | < 0.001 ‡ |
SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; AMI, acute myocardial ischemia; CVD, cerebrovascular disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, the ratio of platelet count multiply neutrophil count to lymphocyte count; SIRI, the ratio of monocyte count multiply neutrophil count to lymphocyte count.
Continuous variables are presented as means with standard deviations.
†t test or Mann-Whitney test.
‡Pearson chi-square test or Fisher’s exact test.